glp-1 agonist therapy consultation preparation Indications for GLP-1/GIP RA Summary Sheet and Beyond! GLP−1 receptor agonists for the

Hazard ratios (HRs) with 95% confidence intervals (CIs) were used to assess primary (MACE) and secondary outcomes (all-cause mortality, CV death, non-fatal MI, non-fatal stroke, and HF hospitalisation) between the two treatment groups

Obesity alone increases the risk of headache and migraine by 27%, suggesting that weight loss itself is an important goal in the symptomatic treatment of IIH (20)

The many alternatives now enable healthcare practitioners to customise the formulation and delivery method according to specific patient preferences and requirements

Detection bias (GLP-1 users are monitored more closely, leading to more diagnoses)

& Singh, P

Evaluate concluded that pharma R&D spending is poised to grow significantly more slowly in the second half of the decade than it did in the first. It projects that the CAGR of more than 9% in 20162023 will shrink to below 3% between 20232030